What We Know About Donald Trump’s COVID-19 Treatment Plan
What We Know About Donald Trump’s COVID-19 Treatment Plan
The President was hospitalized on Friday evening and has been receiving an aggressive treatment of experimental and standard drugs.
What We Know About Donald Trump’s COVID-19 Treatment Plan
What We Know About Donald Trump’s COVID-19 Treatment Plan

The President was hospitalized on Friday evening and has been receiving an aggressive treatment of experimental and standard drugs.

The President was hospitalized on Friday evening and has been receiving an aggressive treatment of experimental and standard drugs.

antibodies
SARS-CoV-2 Antibody Durability
SARS-CoV-2 Antibody Durability
The Scientist Creative Services Team | Oct 2, 2020
Experts will discuss their research on SARS-CoV-2 antibody persistence and immune memory in recovered COVID-19 patients and the implications for protective immunity.
Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy
Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy
Emma Yasinski | Sep 25, 2020
Adeno-associated viral vectors can deliver gene therapies, but AAV-neutralizing antibodies might prevent the medicines from working.
Antibody-Based Drug May Reduce COVID-19 Hospitalizations: Study
Antibody-Based Drug May Reduce COVID-19 Hospitalizations: Study
Lisa Winter | Sep 17, 2020
Eli Lilly reports a 72 percent reduction in hospitalization risk among patients who received its monoclonal antibody compared to those who received a placebo.
Indian Study Shows No Survival Benefit of Plasma in COVID-19
Indian Study Shows No Survival Benefit of Plasma in COVID-19
Alakananda Dasgupta | Sep 15, 2020
A randomized controlled trial on the use of convalescent plasma therapy to treat coronavirus infections—the first in the world to be completed—yields disappointing results, but some doctors are not discouraged.
COVID-19 Antibodies Last for at Least Four Months After Recovery
COVID-19 Antibodies Last for at Least Four Months After Recovery
Amanda Heidt | Sep 2, 2020
The results from a study in Iceland can’t say if a recovered patient’s antibodies can protect them from subsequent reinfection.
Zika Infection Increases Risk of Severe Dengue Fever
Zika Infection Increases Risk of Severe Dengue Fever
Ruth Williams | Aug 27, 2020
A study of Nicaraguan children links prior Zika virus infection with aggravated dengue fever symptoms.
Some COVID-19 Patients Lack Key Structures for Antibody Creation
Some COVID-19 Patients Lack Key Structures for Antibody Creation
Katarina Zimmer | Aug 25, 2020
An absence of germinal centers—which arise during infections to produce long-lived antibody-generating cells—might explain rapidly waning antibody levels in the disease.
Immune Biomarkers Tied to Severe COVID-19: Study
Immune Biomarkers Tied to Severe COVID-19: Study
Ruth Williams | Aug 19, 2020
Increases in the levels of three cytokines are among the features linked to poor outcomes.
Differences in Antibody Responses Linked to COVID-19 Outcomes
Differences in Antibody Responses Linked to COVID-19 Outcomes
Katarina Zimmer | Aug 18, 2020
In a small study of patients hospitalized due to SARS-CoV-2 infection, researchers report distinct early differences between the antibody responses of patients who recovered and those who died, possibly paving the way for a tool to predict disease prognosis.